2022.12-，南京大学医学院附属鼓楼医院，副院长

2019.12-，南京大学医学院附属鼓楼医院，肿瘤中心，主任医师

2017.10-2018.01，哈佛大学医学院/麻省总医院/Dana-Farber癌症中心fellow

2026，胃癌分子标志物鉴定与个体化治疗策略探索. 江苏省医学科技奖青年科技奖（排名1/5）

2024，重大疾病治疗用纳米机器人创新药物技术. 江苏省行业领域优秀科技进展（生物医药领域）（排名5/7）

2023，基于分子标志物的个体化治疗在胃印戒细胞癌中的应用. 江苏省医学引进新技术二等奖（排名2/3）

2020，基于分子分型的胃癌精准病理诊断平台的临床应用. 江苏省新技术引进二等奖（排名3/3）

2019，基于分子标志的胃癌精准医疗新发现及其转化研究. 江苏省科学技术奖一等奖（排名第2/9）

2019，胃癌精准个体化治疗. 江苏省医学科技奖一等奖（排名第2/7）

2017，明胶酶智能靶向纳米药物系统的建立及对胃癌的疗效与机理研究. 教育部科技进步二等奖（排名第5/8）

2024-，《Gastrointestinal Tumors》 主编

2024-，中国抗癌协会整合肿瘤学分会 副主任委员

2025-，中国抗癌协会低氧肿瘤学专委会 副主任委员

2025-，中国临床肿瘤学会胃癌专委会 常务委员

2025-，中国医药生物技术协会精准医疗分会委员会 副主任委员

2024-，江苏省整合医学研究会胃癌专业委员会 主任委员

[1] Shi T†, Liu W†, Luo Y, Liang K, Ren S, Song X, Liu F, Lu C, Hirschhorn D, Wang H, Zhang Y, Cai Y, Wang Y, Pan Y, Liu W, Nie Y, Zhang Z, Yu L, Ding S, Liu B, Merghoub T*, Li Y*, Wei J*. CHI3L3+ immature neutrophils inhibit anti-tumor immunity and impede immune checkpoint blockade therapy in bone metastases. Cancer Cell. 2025 Oct 13;43(10):1937-1957.

[2] Liu W†, Shi T†, Lu C, Che K, Zhang Z, Luo Y, Hirschhorn D, Wang H, Liu S, Wang Y, Liu S, Sun H, Lu J, Liu Y, Shi D, Ding S, Xu H, Lu L, Xu J, Xin J, Liang Y*, Merghoub T*, Wei J*, Li Y*. Human myelocyte and metamyelocyte-stage neutrophils suppress tumor immunity and promote cancer progression. Cell Res. 2025 Aug;35(8):588-606.

[3] Shi T†, Wu Y†, Cai Y†, Luo Y†, Ren S, Cao Y, Tang Y, Jiang Z, Hu S, Xie W, Chen Y, Shen L, Xing H*, Wei J*. Dynamic reprogramming of the tumor immune network via multicycle checkpoint degradation for cancer immunotherapy. Proc Natl Acad Sci U S A. 2026 Mar 10;123(10): e2525047123.

[4] Qi C†, Liu C†, Peng Z†, Zhang Y†, Wei J†, Qiu W†, Zhang X, Pan H, Niu Z, Qiu M, Qin Y, Fang W, Ye F, Li N, Liu T, Liu A, Zhang X, Hu C, Zhang J, Cui J, Lin X, Wang S, Zhang J, Lin T, Qu X, Yuan X, Gong J, Li J, Gao W, Gai L, Wang Y, Yuan D, Li Z, Shen L. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial. Lancet. 2025 Jun 7;405(10494):2049-2060.

[5] Song X†, Lu C†, Shi T†, Wang H, Liu W, Luo Y, Zhou X, Wang Y, Ren S, Yu L, Liu B, Li Y*, Wei J*. MHC-II-restricted neoantigen vaccine reverses immune microenvironment and overcomes resistance to immune-checkpoint inhibitors in cold tumors. Med. 2025 Nov 26:100936.

[6] Shi T, Wei J*. Targeting DKK1 to Remodel the Tumor Microenvironment and Enhance Immune Checkpoint Blockade Therapy. J Clin Oncol. 2025 Jan 20;43(3):350-353.

[7] Wang Y†, Wang H†, Shi T†, Song X, Zhang X, Zhang Y, Wang X, Che K, Luo Y, Yu L, Liu B, Wei J*. Immunotherapies targeting the oncogenic fusion gene CLDN18-ARHGAP in gastric cancer. EMBO Mol Med. 2024; 16(9):2170-2187.

[8] Che K, Luo Y, Song X, Yang Z, Wang H, Shi T, Wang Y, Wang X, Wu H, Yu L, Liu B, Wei J*. Macrophages reprogramming improves immunotherapy of IL-33 in peritoneal metastasis of gastric cancer. EMBO Mol Med. 2024;16(2):251-266.

[9] Wei J, Lu X, Liu Q, Fu Y, Liu S, Zhao Y, Zhou J, Chen H, Wang M, Li L, Yang J, Liu F, Zheng L, Yin H, Yang Y, Zhou C, Zeng P, Zhou X, Ding N, Chen S, Zhao X, Yan J, Fan X, Guan W*, Liu B*. Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial. Nat Commun. 2023 Aug 14;14(1):4904.

[10] Song X, Zhou X, Pan Y, Liang K, Luo Y, Xie W, Lv Z, Yang D, Wang, Y*, Wu X, Wu, Y*, Wei, J*. Schottky Heterojunction Realizes In Situ Vaccine-Like Antitumor Efficacy and Microenvironment Remodeling Upon Near-Infrared Laser Response in Cold Tumors. Adv. Funct. Mater. 2023, 2306734.

[11] Zhang Q, Kuang G, Wang H, Zhao Y*, Wei J*, Shang L*. Multi-Bioinspired MOF Delivery Systems from Microfluidics for Tumor Multimodal Therapy. Adv Sci (Weinh). 2023 Oct 18: e2303818.

[12] Liu Q, Chu Y, Shao J, Qian H, Yang J, Sha H, Cen L, Tian M, Xu Q, Chen F, Yang Y, Wang W, Wang K, Yu L, Wei J*, Liu B*. Benefits of an Immunogenic Personalized Neoantigen Nanovaccine in Patients with High-Risk Gastric/Gastroesophageal Junction Cancer. Adv Sci (Weinh). 2022 Nov 9;10(1):e2203298.

[13] Shi T, Zhang Y, Wang Y, Song X, Wang H, Zhou X, Liang K, Luo Y, Che K, Wang X, Pan Y, Liu F, Yang J, Liu Q, Yu L, Liu B, Wei J*. DKK1 Promotes Tumor Immune Evasion and Impedes Anti-PD-1 Treatment by Inducing Immunosuppressive Macrophages in Gastric Cancer. Cancer Immunol Res. 2022; (12):1506-1524.

[14] Pan Y†, Xue Q†, Yang Y†, Shi T, Wang H, Song X, Luo Y, Liu W, Ren S, Cai Y, Nie Y, Song Z, Liu B, Li JP, Wei J*. Glycoengineering-based anti-PD-1-iRGD peptide conjugate boosts antitumor efficacy through T cell engagement. Cell Rep Med. 2024; 5(6):101590.

[15] Chen H, Shi T, Wang Y, Liu Z, Liu F, Zhang H, Wang X, Miao Z, Liu B, Wan M*, Mao C, Wei J*. Deep Penetration of Nanolevel Drugs and Micrometer-Level T Cells Promoted by Nanomotors for Cancer Immunochemotherapy. J Am Chem Soc. 2021; 143(31):12025-12037.